Metacrine, Inc. (MTCR)
$0.4802
0.00 (0.00%)
Rating:
Recommendation:
-
| Symbol | MTCR |
|---|---|
| Price | $0.4802 |
| Beta | -0.932 |
| Volume Avg. | 0.32M |
| Market Cap | 20.442M |
| Shares () | - |
| 52 Week Range | 0.303-0.676 |
| 1y Target Est | - |
| DCF Unlevered | MTCR DCF -> | |
|---|---|---|
| DCF Levered | MTCR LDCF -> | |
| ROE | -83.77% | Strong Sell |
| ROA | -69.39% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 48.49% | Neutral |
| P/E | - | |
| P/B | 0.55 | Buy |
Latest MTCR news
About
Download (Excel)Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.